Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; ...